Shares of Irvine-based Edwards Lifesciences Corp. were down today on news that the Food and Drug Administration granted an early approval of a less-invasive heart valve developed in Orange County and sold by rival Medtronic Inc.
Edwards’ shares were down 5% to a market value of $7.5 billion in midday trading.
The FDA had set an April 1 deadline to approve Medtronic CoreValve, which is used to treat aortic stenosis, or a narrowing of the body’s main artery, in patients who are too frail to undergo traditional open-heart surgery.
Minneapolis-based Medtronic got the valve in 2009 when it bought Irvine-based CoreValve Inc. for $700 million. It competes with Edwards’ Sapien family of valves.
Earlier this week, a federal jury upheld Edwards’ win in a transcatheter heart valve patent infringement case against Medtronic and awarded it more than $390 million.
Medtronic said it would appeal the decision.